Review

The solute carrier transporters and the brain: Physiological and pharmacological implications

Chengliang Hu\textsuperscript{a,b}, Lei Tao\textsuperscript{a,c}, Xizhi Cao\textsuperscript{a,b}, Ligong Chen\textsuperscript{a,b,c,*}

\textsuperscript{a} School of Pharmaceutical Sciences, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China
\textsuperscript{b} Advanced Innovation Center for Human Brain Protection, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China
\textsuperscript{c} Collaborative Innovation Center for Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China

\textbf{Abstract}

Solute carriers (SLCs) are the largest family of transmembrane transporters that determine the exchange of various substances, including nutrients, ions, metabolites, and drugs across biological membranes. To date, the presence of about 287 SLC genes have been identified in the brain, among which mutations or the resultant dysfunctions of 71 SLC genes have been reported to be correlated with human brain disorders. Although increasing interest in SLCs have focused on drug development, SLCs are currently still under-explored as drug targets, especially in the brain. We summarize the main substrates and functions of SLCs that are expressed in the brain, with an emphasis on selected SLCs that are important physiologically, pathologically, and pharmacologically in the blood-brain barrier, astrocytes, and neurons. Evidence suggests that a fraction of SLCs are regulated along with the occurrences of brain disorders, among which epilepsy, neurodegenerative diseases, and autism are representative. Given the review of SLCs involved in the onset and procession of brain disorders, we hope these SLCs will be screened as promising drug targets to improve drug delivery to the brain.

© 2019 Shenyang Pharmaceutical University. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Solute carriers (SLCs) are a major superfamily of membrane transporters with 439 members (excluding pseudogenes) classified into 65 families, and they mediate the exchange of substances, such as ions, nutrients, signaling molecules and drugs across biological membranes ([1–4] and http://slc.bioparadigms.org). The brain is the body's most delicate and complicated organ and maintains its internal homeostasis with the assistance of the blood–brain barrier (BBB) and blood–cerebrospinal fluid barrier (BCSFB). The brain...
| Families                                                                 | Predominant substrates                                                                 |
|------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| SLC1: high-affinity glutamate and neutral amino acid transporter family | Glu, Asp, Ala, Ser, Cys, Thr, Gln, Asn  
| SLC2: facilitative GLUT transporter family                             | glucose, galactose, fructose, mannose  
| SLC3: heavy subunits of the heteromeric amino acid transporters        | neutral, dibasic and large amino acids  
| SLC4: bicarbonate transporter family                                    | bicarbonate  
| SLC5: sodium glucose cotransporter family                              | glucose, myo-inositol, biotin, pantothenic acid, choline, lactate, ketone bodies  
| SLC6: sodium- and chloride-dependent neurotransmitter transporter family | GABA, Gly, Pro, Leu, Ala, dopamine, serotonin, creatine  
| SLC7: cationic amino acid transporter/glycoprotein-associated family   | neutral and cationic amino acids  
| SLC8: Na⁺/Ca²⁺ exchanger family                                        | Na⁺, Ca²⁺, Li⁺  
| SLC9: Na⁺/K⁺ exchanger family                                          | Na⁺, K⁺, Li⁺, H⁺, NH₄⁺  
| SLC10: sodium bile salt cotransport family                             | bile acids  
| SLC11: proton-coupled metal ion transporter family                     | Fe²⁺, Cd²⁺, Co²⁺, Cu²⁺, Mn²⁺, Zn²⁺  
| SLC12: electroneutral cation-coupled Cl⁻ cotransporter family          | Na⁺, K⁺, Cl⁻  
| SLC13: human Na⁺-sulfate/carboxylate cotransporter family              | citrate  
| SLC14: urea transporter family                                          | urea  
| SLC15: proton oligopeptide cotransporter family                        | di- and tri-peptides, protons, His  
| SLC16: monocarboxylate transporter family                              | lactate, pyruvate, ketone bodies, monocarboxylates  
| SLC17: vesicular glutamate transporter family                          | Glu, sialic acid, nucleotides  
| SLC18: vesicular amine transporter family                              | monoamines, acetylcholine, spermine, spermidine  
| SLC19: folate/thiamine transporter family                               | folate, thiamine  
| SLC20: type III Na⁺−phosphate cotransporter family                    | inorganic phosphate  
| SLC21: organic cation/anion/zwitterion transporter family              | thyroid hormones, estrone-3-sulfate and taurocholate, bile salts  
| SLC22: organic cation/anion/zwitterion transporter family              |  
| SLC23: Na⁺−dependent ascorbic acid transporter family                  | ascorbic acid  
| SLC24: Na⁺/(Ca²⁺−K⁺) exchange family                                   | Na⁺, Ca²⁺, K⁺  
| SLC25: mitochondrial carrier family                                    | a variety of solutes  
| SLC26: multifunctional anion exchanger family                          | Cl⁻, HCO₃⁻, SO₄²⁻, OH⁻  
| SLC27: fatty acid transporter family                                   | long-chain fatty acids, very long chain fatty acids  
| SLC29: facilitative nucleoside transporter family                       | nucleosides, serotonin, dopamine  
| SLC30: Zinc efflux family                                              | zinc  
| SLC31: copper transporter family                                        | copper  
| SLC32: vesicular inhibitory amino acid transporter family              | GABA, glycine  
| SLC33: Acetyl-CoA transporter family                                   | acetyl-CoA  
| SLC35: nucleoside-sugar transporter family                              | CMP-sialic acid, PAPS, GDP-fucose  
| SLC36: proton-coupled amino acid transporter family                    | Pro, Trp  
| SLC37: sugar-phosphate/phosphate exchanger family                     | glucose-6-phosphate  
| SLC38: system A and system N sodium-coupled neutral amino acid transporter family | neutral amino acids  
| SLC39: metal ion transporter family                                     | Zn, Mn, Fe, Cd  
| SLC41: Mg²⁺-like magnesium transporter family                          | Mg²⁺  
| SLC43: Na⁺−independent, system-1-like amino acid transporter family    | L-BCAAs, amino alcohols  
| SLC44: choline-like transporter family                                 | choline  
| SLC45: H⁺/sugar cotransporter family                                   | glucose, galactose, fructose  
| SLC46: folate transporter family                                        | folates  
| SLC47: multidrug and toxin extrusion family                            | metformin, memantine, MPP, tetraethylammonium  
| SLC48: heme transporter family                                          | heme  
| SLC49: FLVCR-related transporter family                                | heme  
| SLC50: sugar efflux transporters                                       | glucose  
| SLC52: riboflavin transporter family                                   | riboflavin  
| SLC53: phosphate carriers                                              | phosphate  
| SLC54: mitochondrial pyruvate carriers                                 | pyruvate  
| SLC55: mitochondrial cation/proton exchangers                         | Ca²⁺, K⁺, H⁺  
| SLC56: sideroflexins                                                   | Ser  

(continued on next page)
Table 1 (continued)

| Families                      | Predominant substrates                        |
|-------------------------------|------------------------------------------------|
| SLC57: NIPA-like magnesium transporter family | Mg$^{2+}$, Sr$^{2+}$, Fe$^{2+}$, Co$^{2+}$, Ba$^{2+}$ |
| SLC58: MagT-like magnesium transporter family | Mg$^{2+}$                                     |
| SLC59: sodium-dependent lysophosphatidylcholine symporter family | lysophosphatidylcholine (LPC)                  |
| SLC60: glucose transporters   | glucose                                        |
| SLC61: molybdate transporter family | molybdate                                     |
| SLC62: pyrophosphate transporters | pyrophosphate                                  |
| SLC63: sphingosine-phosphate transporters | sphingolipid                                   |
| SLC64: golgi Ca$^{2+}$/H$^{+}$ exchangers | Ca$^{2+}$, H$^{+}$, Mn$^{2+}$                 |
| SLC65: NPC-type cholesterol transporters | cholesterol                                   |

parenchymal cells mainly consist of neurons, astrocytes, microglia, and oligodendrocytes. A total of 287 SLC genes have been identified in brain, especially in the cells that comprise the barriers and parenchymal cells, through which a variety of substrates, including sugars, amino acids, vitamins, neurotransmitters, and inorganic/metal ions are transported (Table 1, slc.bioparadigms.org and ascot.cs.jhu.edu). SLCs expressed in the endothelial cells of the BBB contribute to keeping the brain isolated from toxic substances and are necessary for absorbing essential components from the blood, while SLCs expressed in the choroid plexus of BCSFB regulate secretion and re-absorption of the cerebrospinal fluid (CSF). SLCs expressed in neurons and glial cells play irreplaceable roles in brain homeostasis maintenance and drug response regulation. Therefore, SLCs participate in cell type-specific drug delivery, and they are considered direct drug targets for treatment of various conditions [5–7]. The basic characteristics of brain-expressed SLCs are summarized in Table 1.

Membrane transport can be divided into two types: passive and active [8–10]. Passive transport can be divided into diffusion and facilitated diffusion, while active transport includes primary active transport (transport protein contains ATPase, including ABC (ATP-binding cassette) transporters and P-type ATPases) and secondary active transport [11,12]. SLCs function by facilitated diffusion and secondary active transport. Passive transport facilitates the movement of solutes and ions across the membrane and is usually accompanied by spontaneous and stochastic conformational changes. For example, SLC2A1 transports glucose across the BBB in a passive transport profile. Secondary active transporters transport the substrates and another solute or solutes (most typically ions) in the same or opposite directions utilizing preexisting gradients of ions as a source of energy [13]. For instance, SLC1A2, which is mainly localized in astrocytes and responsible for over 90% of total glutamate uptake, co-transport Na$^{+}$ and H$^{+}$ and antiports K$^{+}$ to achieve glutamate transport [14]. Symporters and antiporters are two types of secondary active transporters that utilize downhill ion gradients as the driving force in the same (symporter) or opposite (antiporter) direction of substrate transport [15,16].

SLCs have been frequently reviewed as drug targets, and developing new drugs with SLCs in mind can help improve bioavailability of the drugs due to SLCs involvement in drug disposition, drug–drug interactions, and corresponding toxicity [17–22]. We aim to summarize the physiological characteristics of SLCs in the brain and the potential of SLCs to be efficient drug targets for the treatment of brain disorders.

2. The characteristics of SLCs in the brain

2.1. Localization of SLCs in the brain

2.1.1. The BBB and BCSFB

The BBB is formed by endothelial cells, astrocyte end-feet, and pericytes. Disruption of the BBB is often the result of increased permeability, leading to various brain disorders, such as multiple sclerosis [23], hypoxia and ischemia [24], Alzheimer’s disease (AD) [25], and epilepsy [26]. Passive diffusion, ABC and SLC mediated transport, transcytosis, and mononuclear cell migration are all available routes across the BBB. SLCs expressed in the BBB, especially members of the SLC7A, SLCO, and SLC22A families, have been compared to SLCs in other regions within the brain [27–30]. SLCs in the BBB mediate the transport of various substrates and play crucial roles in brain homeostasis and drug delivery. SLC22A5, a well studied SLC in the BBB that act upon carnitine, can stimulate the synthesis of acetylcholine, decrease oxidative stress, and prevent neurodegeneration [31]. SLC22A5 possesses great potential to facilitate drug delivery across the BBB through the following two strategies: (1) a dual prodrug strategy; L-carnitine conjugated with nipecotic acid as a ‘dual prodrug’ passes through the BBB via SLC22A5 [32]; (2) SLC22A5-targeted nanoparticles; SLC22A5 is expressed in the glial cells, and L-carnitine-conjugated nanoparticles have been developed to enhance the permeability of nanoparticles across the BBB and uptake by glioma [30,33]. Another representative example of SLCs in the BBB is the SLCO family. Members of SLCO can trigger the blood-to-brain transport of opioid analogs, such as deltorphin II and DPDEP ([D-penicillamine(2,5)]-enkephalin), and are potential targets for the treatment of pain and cerebral hypoxia [34,35].

The turnover rate of human CSF is about 4 times per day, which requires a tightly-regulated ion and water transport system. Horace et al. (2012) used in situ hybridization data of SLC genes in mice to show that 80% of SLCs were expressed in the BCSFB and 28 were expressed at the highest levels [36]. These SLCs were involved in CSF production, drug
Table 2 – Substrates of the brain SLCs. Seven kinds of endogenous substrates and the examples are shown for SLC families. Data were retrieved from genecards.org.

| Substrates             | SLCs                  | Examples of substrates                                      |
|------------------------|-----------------------|-------------------------------------------------------------|
| amino acids            | SLC1, 3, 7, 17, 32, 38, 43 | Asp, Arg, Glu, Gln, Gly                                     |
| energetic substrates   | SLC2, 5, 37, 45, 50, 60 | glucose, glucose-6-phosphate                                |
| neurotransmitter       | SLC1.6, 17, 18, 25, 29, 44 | serotonin, dopamine, choline, Glu, Gly                      |
| inorganic/metal ions   | SLC4, 8, 9, 11, 12, 13, 20, 24, 26, 30, 31, 39, 41, 53, 58, 57, 61, 62, 64 | Na⁺, Ca²⁺, Fe²⁺, zinc, chloride                            |
| vitamin                | SLC19, 23, 46, 52     | thiamine, vitamin C, folates, riboflavin                    |
| organic anions         | SLC21, 22             | thyroid hormones, bile acids, some steroidal compounds, organic cations, carnitine |
| miscellaneous          | SLC10, 14, 15, 16, 18, 27, 33, 48, 49, 54, 59, 63, 65 | lactate, pyruvate, creatine, acetyl-CoA, long-chain fatty acids |

clearance from the CSF, and transports of inorganic/metal ions, amino acids, carbohydrates, fatty acids, monoamines, and other substrates. Specific inhibitors or gene-knockout mouse models are in urgent need for further studies in the roles of SLCs in the BCSFB.

2.1.2. Astrocytes and neurons

Astrocytes play essential roles in various brain activities, in part by manipulating SLC functions. Despite the fact that most SLC families have members expressed in astrocytes, the characterization of their functions remains at initial stage and require further investigation. The functional expressions of SLCs in astrocytes have been summarized with an emphasis on several well-established families, including SLC10, SLC22A, and SLC29A, which are organic anion transporter family, an organic cation/anion/zwitterion transporter family, and a facilitative nucloside transporter family, respectively [37,38]. These SLCs in astrocytes have the potential to be targeted by drugs against various CNS disorders. For example, SLC22A3 is expressed in astrocytes in several brain regions, including striatum, hippocampus, and hypothalamic nuclei, and is capable of transporting histamine, norepinephrine, and epinephrine. The inhibition of SLC22A3 is expected to improve the efficacy of anti-depressant drugs [37,39]. SLC1A2 and SLC1A3 are Na⁺-dependent glutamate transporters mainly expressed in astrocytes and function in modulating glutamatergic activity in the brain. Dysfunction or mutation of SLC1A2 and SLC1A3 have been extensively studied in many brain disorders, including epilepsy, AD, Parkinson’s disease (PD), amyotrophic lateral sclerosis, major depressive disorder, and addiction [14,40-42].

All of the 60 SLC families in the brain contain members expressed in neurons. The presence of either SLC17A6/A7 or SLC32A1 defines excitatory and inhibitory neurons, respectively. SLC17A6 and SLC17A7 are mainly expressed in glutamatergic neurons mediating glutamate reuptake into synaptic vesicles at excitatory presynaptic nerve terminals [43]; SLC32A1 is expressed in GABAergic neurons and mediates the uptake of GABA and glycine into the synaptic vesicles [44]. SLC17A6/A7 and SLC32A1 may also be present in the same nerve terminals in subsets of neurons, indicating that both glutamate and GABA can be released from a single nerve terminal [45,46]. SLC17A6/A7 and SLC32A1 play important roles in normal glutamatergic and GABAergic neurotransmission [47]. Reduced expression of SLC17A7 leads to enhanced anxiety, depressive-like behavior and impaired recognition memory in mice [48]. The SLC18A1 family is responsible for the transport of other small molecule neurotransmitters besides glutamate and GABA into synaptic vesicles. Vesicular acetylcholine transporter SLC18A3 over-expression induces major modifications of cholinergic interneuron morphology and function [49]. Reduced SLC18A3 favors antidepressant behaviors in female mouse brain [50]. The SLC6A family transports amino acids or amino acid-like substrates into cells in a Na⁺-dependent manner. SLC6A1 and SLC6A11 transport GABA into neurons and glial cells, respectively; SLC6A2 transports norepinephrine; SLC6A3 transports dopamine and SLC6A4 transports serotonin [51,52]. SLC6A3, one of the most investigated neurotransmitter transporters, is involved in the pathogenesis of a number of brain disorders [53,54].

SLCs can also be detected in other brain cell types, including oligodendrocytes and microglial cells. For example, SLC4A1, localized to oligodendrocytes, is involved in membrane synthesis for cell growth and remyelination [55]. SLC2A1 dominates glucose uptake in microglia under inflammatory conditions and targeting SLC2A1 could be effective for ameliorating neuroinflammation [56]. Nevertheless, given the lack of functional studies of SLCs expressed in oligodendrocytes and microglial cells, these are not summarized in this topic.

2.2. Substrates and functions of the SLCs

Various substrates are transported by 60 families of SLCs expressed in the brain (Table 1) and include energetic substrates, amino acids, neurotransmitters, organic ions, metals, organic anions, and vitamins, as summarized in Table 2. The multiple functions of SLCs in the brain are fulfilled by transport of these substrates. Specific functions of SLCs are summarized in the following sections.

2.2.1. SLCs function in energy metabolism

The energy demands of the brain are very high and glucose is the obligatory energy substrate of the adult brain [57,58]. Glucose is a polar, hydrophilic molecule that is transported largely via the glucose transporter SLC2A [59]. Ten SLC2A members are expressed in the brain, among which SLC2A1...
and SLC2A3 play a major role in brain glucose uptake [60,61]. SLC2A1 deficiency syndrome, characterized by a range of phenotypes that include epilepsy, intellectual disability, and ataxia, is a rare neurological disorder that impairs glucose transport across the BBB [62]. The transport of glucose in different neural cells is a highly specified process regulated by different SLCs [63]. The utilization rate of glucose in astrocytes is higher than in neurons, and stimulation of glucose utilization in astrocytes is mediated by the glutamate transporter SLC1A [64]. Glycogen is the major store of glucose in brain and is mainly found in astrocytes. Glycogen turnover and conversion to lactate in the brain is extremely rapid, and is used for glutamate synthesis or producing glucose [65]. Astrocyte-neuron lactate transport mediated by SLC16A is required for long-term memory formation [65,66]. Further investigation on SLCs will help to understand the homeostatic regulation of energy and glucose metabolism in the brain.

2.2.2. SLCs function in the glutamate/GABA-glutamine cycle

The SLCs regulate the flux of nutrients and metabolites to keep the brain in homeostasis, supply energetic substrates, fulfill neurotransmission, and remove toxins. Among these functions, it is noteworthy that the brain receives about 20% of the total glucose in the body and 80% of the energy is used for maintaining the homeostasis of the glutamate/GABA-glutamine cycle [67]. In neurons, the neurotransmitters glutamate and GABA are transported to presynaptic terminals by vesicular transporters of SLC17A6/A7 and SLC32A1, respectively. After release and binding with receptors in the postsynaptic neurons, extracellular glutamate and GABA are transported into astrocytes via SLC1A2/A3 and SLC6A1, respectively. Glutamate/GABA is then converted to glutamine and subsequently transferred from mature astrocytes via SLC38A3/A5 and from reactive astrocytes via SLC1A5 [68,69]. The glutamine is then imported into neurons via SLC38A1/A2/A7 and SLC1A5 and re-converted to glutamate and GABA (Fig. 1) [69–71]. The dysfunction of these SLCs may give rise to excitotoxicity caused by accumulation of synaptic glutamate, which can thus be involved in the pathogenesis of various brain disorders, such as AD, PD, epilepsy, autism, and schizophrenia [41].

2.2.3. SLCs function in neurotransmitter release and reuptake

Synaptic transmissions require the controlled release of neurotransmitters packaged in synaptic vesicles. Released transmitters diffuse across the synaptic cleft, bind to specific postsynaptic receptors, and are rapidly cleared from the synaptic cleft by uptake into the presynaptic neuron or glial cells. During this process, neurotransmitter transporters in neuronal and glial plasma

---

**Fig. 1** - The main solute carrier transporters involved in glutamate/GABA-glutamine cycle. Glutamate is packaged into synaptic vesicles in pre-synaptic neurons by SLC17A6/A7. After release into the synaptic cleft and stimulating post-synaptic neurons, the signal is terminated by astroglial uptake of glutamate via SLC1A2/A3. Glutamate is converted to glutamine via glutamine synthase (GS). Glutamine is transported out of astrocytes through SLC38A3/A5, shuttled to neurons via SLC38A2/A7/SLC1A5, and converted to glutamate by phosphate-activated glutaminase (PAG) to complete the glutamate–glutamine cycle. GABA is packaged into synaptic vesicles by SLC32A1 and released into the synaptic cleft. SLC6A11 and SLC6A1 are responsible for GABA uptake in astrocytes and neurons, respectively. GABA is metabolized to α-ketoglutarate (α-KG) via TCA cycle and then glutamate. The following steps are similar to the glutamatergic synapses until glutamate is converted to GABA by glutamate decarboxylase (GAD) in GABA-ergic neurons. GABA is repackaged in vesicles for further synaptic release.
membranes and vesicular neurotransmitter transporters that package neurotransmitters into secretory vesicles in presynaptic neurons play important roles. As small molecule neurotransmitters package into synaptic vesicles, SLC18A2/A3 packages acetylcholine, histamine, dopamine, norepinephrine, epinephrine, and serotonin; SLC17A6/A7 packages glutamate; and SLC32A1 packages GABA [72,73]. As for small molecule neurotransmitter reuptake, SLC1A1/A2 transports glutamate; SLC5A7 transports choline (released from the breakdown of acetylcholine in the synaptic cleft); and SLC6A transports dopamine, norepinephrine, GABA, and serotonin [52,74,75]. Disturbances in the transport of neurotransmitters have been implicated in various brain disorders, such as AD and PD [51].

2.2.4. SLCs function in the BBB
Another noteworthy function of SLCs in the brain is transport across the BBB to strictly control exchanges of substrates between the blood and the brain, including energetic substrates, amino acid, ions and other miscellaneous substrates [27,76]. The BBB is the most significant barrier in the brain that prevents approximately 98% of small molecule reagents from passing when treating CNS-related disease [77]. Therefore, SLCs in the BBB have a great potential to be utilized for the purpose of improving the delivery of drugs, prodrugs, and nanoparticles into the brain [78-80].

3. SLCs in drug development for brain disorders

Our understanding of the physiological and pathological functions and molecular mechanisms of SLCs has exploded in the last decade [19,81,82]. Nevertheless, SLCs still have not been well evaluated in brain disorders and have been under-utilized as drug targets for the treatment of brain disorders. The utilizations of SLCs have been summarized in the treatment of major depression, attention deficit and hyperactivity disorder, epilepsy, movement disorders, psychosis, PD, and other brain disorders [17]. Targeting SLCs to ameliorate more brain disorders is becoming a focus of investigations. Particularly, manipulation of SLCs for drug/prodrug transmembrane transport, especially blood-to-brain transport, has also drawn the attention of researchers [83]. In the next section, we summarize the typical brain disorders that can be caused by SLCs dysfunction or mutation and manipulation of SLC for improving drug transport.

3.1. SLCs as potential drug targets in treatment of brain disorders

3.1.1. SLCs in epilepsy
Epilepsy is one of the most common neurological diseases affecting approximately 70 million individuals [84]. It is characterized by recurrent, unprovoked seizures with multifactorial pathophysiologic mechanisms. Out of the 71 SLC genes expressed in the brain whose mutations or dysfunctions have been reported to be correlated with human brain disorders, about 22% are correlated with epilepsy or epileptic encephalopathy (Table 3). SLC12A2 and SLC12A5 are two typical transporters that have been extensively studied in attempts to understand the mechanism and explore new therapeutic targets of epilepsy [85-87]. SLC12A2 mediates chloride ion (Cl−) uptake and favors depolarizing responses to GABA, while SLC12A5 is the main Cl− extruding transporter. Alterations in the balance of SLC12A2 and SLC12A5 activity are correlated with epileptogenesis. The SLC12A2 inhibitor bumetanide has been shown to exert antiepileptic effects [88]. Perturbations in the glutamate/GABA-glutamine cycle, such as the disruption of extracellular glutamate clearance from the synaptic cleft, could also contribute to the development of epilepsy [89]. Indeed, SLC1A2, which is responsible for regulating extracellular glutamate homeostasis by uptake of glutamate in astrocytes, is reported to cause epilepsy when mutated [90,91]. Increased SLC1A2 expression reduces epileptogenic processes in a status epilepticus mouse model and thus enhancing SLC1A2 expression is a potential therapeutic approach for epilepsy [91]. The mutation of SLC6A1 and SLC6A11, which are responsible for the reuptake of GABA from the synaptic cleft into neurons and astrocytes, has also been reported in patients with epilepsy [92,93]. Tiagabine, which increases the brain levels of GABA by targeting SLC6A1, is used for treating epilepsy [134]. Another noteworthy SLC that has a relationship with epilepsy is SLC13A5, whose mutation induces neonatal epilepsy [94-97]. SLC13A5, a sodium-coupled tricarboxylate substrate transporter, is expressed at high levels in astrocytes, but is expressed at lower levels in neurons [98]. SLC13A5 deficiency results in a loss of citrate transport, causing the short supply of energy, bicarbonate, and biosynthetic precursors in brain [99]. Metabolomics profiling of SLC13A5-deficient patients revealed that dysfunction of SLC13A5 function disrupted metabolites of the citric acid cycle and neurotransmitters [100].

3.1.2. SLCs in Alzheimer’s disease (AD) and Parkinson’s disease (PD)
AD is the most common neurodegenerative disease and is a significant concern for aging populations [101]. Although the specific pathogenesis mechanisms of AD have not been defined, pathological characteristics that contribute to progressive neurodegeneration are under extensive exploration. Brain glucose metabolism was reported to decline in AD patients [102]. SLC2A1 expression is decreased in cerebral microvessels and cortex of AD patients and is associated with Aβ deposition [103-105]. Loss of neuron-specific SLC2A3 was found in AD brain along with tau hyperphosphorylation [102]. The expression level of SLC2A3 was confirmed to be regulated by an emerging Alzheimer’s therapeutic target, BDNF (brain-derived neurotrophic factor) [106]. SLC2A2 was significantly elevated in AD patients due to activation of astrocytes [102]. Dysregulation in glutamate homeostasis has also been demonstrated in AD animal models and AD patients, which suggests a role for glutamate transporters in the onset and progression of AD [107]. SLC1A2 is decreased in AD brains, especially in hippocampal tissue and prefrontal cortex from late-stage AD patients [108-110]. Abdul et al. showed that SLC1A2 had reduced expression during the progression from mild cognitive impairment to AD [111]. It is believed that the study of the transporting mechanism associate with AD will help to clarify the pathogenesis of this disease.
Table 3 - Brain disorders associated with SLCs. Examples of brain disorders in SLC knockout/overexpression mice/rats, or mice/rats models of human disease in which SLCs are modified are shown. Human brain disorders caused by SLC gene dysfunction are also shown. Data on human disorders were retrieved from omim.org.

| SLCs | Brain disorders in mouse/rat | Human brain disorders caused by SLC gene dysfunction |
|------|-----------------------------|-----------------------------------------------------|
| SLC1A1/EAAT3 | Obsessive-compulsive disorder, schizophrenia | Dicarboxylic amino aciduria (glutamate-aspartate transport defect) |
| SLC1A2/EAAT2 | Epilepsy | Epileptic encephalopathy |
| SLC1A3/EAAT1 | Alzheimer’s disease | Episodic ataxia |
| SLC1A4/ASCT1 | Schizophrenia | Epileptic encephalopathy, developmental delay, microcephaly and hypomyelination, severe intellectual disability |
| SLC1A5/ASCT2 | Schizophrenia | No |
| SLC1A6/EAAT4 | No | Hypoxia, ischemia |
| SLC2A1/GLUT1 | Epilepsy and metabolic dysfunction | Glucose transporter type 1 deficiency syndrome, intractable infantile seizures, complex motor disorder, intellectual impairment, low CSF glucose (hypoglycorrhachia), microcephaly |
| SLC2A4/GLUT4 | Impaired glucose tolerance, decreased insulin sensitivity | No |
| SLC4A10/NBCn2 | Small brain ventricles, reduced neuronal excitability | Epilepsy, mental retardation |
| SLC5A7/CHT | No | Attention-deficit hyperactivity disorder |
| SLC6A1/GAT1 | Epilepsy | Myoclonic-ataxic epilepsy |
| SLC6A3/DAT | Attention-deficit/hyperactivity disorder, Parkinson’s disease | Dopamine transporter deficiency syndrome, parkinsonism-dystonia |
| SLC6A4/5-HTT | Anxiety | Obsessive-compulsive disorder, anxiety-related personality traits, bipolar affective disorder, alcoholism, migraine with aura, sudden infant death, pulmonary hypertension |
| SLC6A5/GlyT2 | Hyperekplexia | Cerebellar ataxia, Lichtenstein-Knorr syndrome |
| SLC6A8/Ct | Cognitive deficits | Cerebral creatine deficiency syndrome |
| SLC6A9/GlyT1 | Epilepsy, schizophrenia | Glycine encephalopathy |
| SLC6A11/GAT3 | Epilepsy | Intellectual disability, epilepsy and stereotypic behavior |
| SLC6A12/BGT1 | No | Epilepsy |
| SLC6A15/V7-3 | Depression | Major depression |
| SLC6A17/NNT4 | No | Autosomal recessive intellectual disability |
| SLC7A3/CAT3 | No | Autism spectrum disorder |
| SLC7A5/LAT1 | Glioma | Autism spectrum disorder |
| SLC8A1/NCX1 | No | No |
| SLC8A2/NCX2 | Glioblastoma, cerebral ischemia | No |
| SLC8A3/NCX3 | Cerebral ischemia | No |
| SLC9A1/NHE1 | Glioma | Cerebellar ataxia, Lichtenstein-Knorr syndrome |
| SLC9A6/NHE6 | Christianson syndrome | Mental retardation, X-linked syndromic, christianson type |
| SLC9A7/NHE7 | No | Nonsyndromic X-linked intellectual disability |
| SLC9A9/NHE9 | Autism | Autism susceptibility 16, attention-deficit/hyperactivity disorder |
| SLC10A4/P4 | Cognitive impairments | No |
| SLC11A2/DCT1 | Parkinson’s disease | No |
| SLC12A2/NKCC1 | Stroke, epilepsy | Epilepsy |
| SLC12A5/KC2 | Epilepsy | Epilepsy |
| SLC12A6/KC3 | Hypertension | Andermann syndrome |
| SLC13A5/NaCT | No | Kohlschütter-Tönz syndrome, epilepsy |
| SLC16A2/MCT8 | No | Severe psychomotor disability of unknown etiology, Allan-Herndon-Dudley syndrome |
| SLC16A4/MCT4 | Glioma | Epilepsy |
| SLC16A7/MCT2 | Epilepsy | Epilepsy |
| SLC17A5/AST | No | Free sialic acid storage diseases |
| SLC17A6/VGLUT2 | Epilepsy | Gnathodiaphyseal dysplasia, tendinosis |
| SLC17A7/VGLUT1 | Depression, Alzheimer’s disease | Spino cerebellar Ataxia 27, deafness autosomal dominant 25 |
| SLC17A8/VGLUT3 | Anxiety | deafness, autosomal dominant 25 and deafness, autosomal recessive 6 |
| SLC18A2/VMAT2 | Opioid dependence, alcohol and nicotine dependence | Parkinsonism-dystonia, infantile, 2 and brain |
| SLC18A3/VAcHt | Impaired short-term object recognition memory | dopaminergic-serotonin vesicular transport disease |
| SLC19A1/RFC1 | No | Mynasthenic syndrome, congenital, 21, presynaptic and |

(continued on next page)
Table 3 (continued)

| SLCs                  | Brain disorders in mouse/rat | Human brain disorders caused by SLC gene dysfunction |
|-----------------------|------------------------------|------------------------------------------------------|
| SLC19A3/Thy1    | No                           | Basal ganglia disease                                |
| SLC20A2/Pit2     | No                           | Brain calcification, acute ischemic stroke           |
| SLC01C1/OATP14  | No                           | Brain-specific hypothyroidism and neurodegeneration  |
| SLC22A6/OAT1     | Learning and memory impairment | No                                                   |
| SLC22A17/BOCT   | No                           | Deafness, autosomal dominant 53 and deafness, autosomal recessive 5 |
| SLC22A18/ORCTL2 | No                           | Glioma                                               |
| SLC23A3/SVCT3   | No                           | Epilepsy                                             |
| SLC24A4/NCX4    | No                           | Alzheimer’s disease                                  |
| SLC25A4/ANT1    | Bipolar disorder             | No                                                   |
| SLC25A5/ANT2    | No                           | Intellectual disability                              |
| SLC25A12/AGC1  | Hypomyelination and neuronal defects | Epileptic encephalopathy, early infantile, 39 and asperger syndrome |
| SLC25A17/PMP34  | No                           | Cerebral degeneration                                |
| SLC25A19/DNC    | No                           | Microcephaly, amish type and thiamine metabolism dysfunction syndrome 4, bilateral striatal necrosis |
| SLC25A22/GC1    | No                           | Epileptic encephalopathy, early infantile, 3        |
| SLC25A27/UCP4   | No                           | Multiple sclerosis                                   |
| SLC25A37/MFRN1  | No                           | Major depressive disorder                            |
| SLC25A39/CGI69  | No                           | Childhood absence epilepsy                           |
| SLC25A42/MCR67  | No                           | Epileptic encephalopathy                            |
| SLC25A46/HMSN6B | Neurodegeneration            | Neuropathy, hereditary motor and sensory, lethal congenital pontocerebellar hypoplasia |
| SLC27A4/FATP4   | No                           | Autism                                               |
| SLC29A1/ENT1    | Huntington’s disease         | Huntington’s disease                                 |
| SLC29A4/ENT4    | No                           | Autism                                               |
| SLC30A1/2NT1    | Ischemic stroke, neonatal seizures | No                                                   |
| SLC30A3/2NT3    | No                           | Schizophrenia                                        |
| SLC30A4/2NT4    | No                           | Alzheimer’s disease                                  |
| SLC30A10/2NT10  | No                           | Hereditary hypermanganesemia                         |
| SLC31A1/CTR1    | Manganese-induced neurotoxicity | No                                                   |
| SLC32A1/VGAT    | Anxiety, epilepsy, excitotoxicity, cortical dysplasia | No                                                   |
| SLC33A1/AT1    | Alzheimer’s disease          | Neurodegeneration                                     |
| SLC35A1/CST     | No                           | Encephalopathy                                       |
| SLC35A3/AMRS    | No                           | Autism spectrum disorder, epilepsy                   |
| SLC45A1/DNB5   | No                           | Intellectual developmental disorder with neuropsychiatric features and autosomal recessive non-syndromic intellectual disability |
| SLC52A3/RVFT3  | No                           | Brown-Vialetto-Van Laere syndrome                    |
| SLC53A1/XPR1   | No                           | Brain calcification                                  |
| SLC55A1/LETM1  | No                           | Epileptic seizures                                   |
| SLC59A1/MFS2DA  | Blood-brain barrier disruption | Microcephaly                                          |
| SLC62A1/ANKH    | No                           | Seizure                                              |
| SLC65A1/NPC1   | No                           | Niemann-Pick disease type C                          |

PD usually starts with the early prominent death of dopaminergic neurons in the substantia nigra and is associated with typical parkinsonian motor symptoms [112,113]. A compensatory mechanism related to SLC6A3 mediating the unidirectional rapid reuptake of dopamine dependent on the sodium gradient was shown to be effective [114,115]. Dopamine transporter imaging has become a widely used diagnostic tool for PD and SLC7A5 facilitates L-DOPA transport into the brain for the treatment of PD [116–118].

3.1.3. SLCs in autism

Autism spectrum disorders (ASD) are a group of genetic disorders characterized by impairment in social interactions, language, and speech, as well as restricted repetitive behaviors. Gene mutations are important factors in the development of ASD. Tärlungeanu et al. identified several patients with autistic traits carrying mutations in SLC7A5 [119], a gene encoding a neutral amino acid transporter localized in the BBB. Branched chain amino acids (BCAA), substrates of SLC7A5 at the BBB, regulate GABAAergic transmission, which can lead to the development of novel therapeutic strategies for autism [119]. Genetic variants of SLC19A1 and SLC25A12, folate and amino acid transporters, respectively, are associated with childhood ASD [120]. The fatty acid transporter-encoding gene SLC27A4 p.Gly209Ser mutant results in more fatty acid uptake into an endothelial cell line, and this functional change may be associated with ASD pathophysiology [121].
3.1.4. SLCs in other brain disorders

Although the underlying mechanisms of brain disorders have not been well characterized, many case reports have shown that SLCs are significantly involved in the occurrence and development of brain disorders (for a summary, see Table 3), such as attention-deficit hyperactivity disorder, mental retardation, Huntington’s disease (HD), and major depressive disorders. Many drugs/inhibitors targeting SLCs have been tested and utilized in brain disorders. UCPH-101 has been shown to exert sustained inhibition of SLC1A3 [122]. Tiagabine exerts anticonvulsant activity via inhibition of uptake by SLC6A1 [123]. High throughput screening has led to the discovery of a structurally novel class of inhibitors of SLC6A9 [124]. Deutetrebenezine, a novel SLC18A2 inhibitor, is effective for the treatment of involuntary movements in patients with tardive dyskinesia [125]. Tetrabenazine, which depletes presynaptic dopamine by blocking SLC18A2, is a US Food and Drug Administration-approved drug for chorea in HD [126]. These findings may lead to the development of therapeutic treatments for certain neurological disorders.

3.2. SLCs for improving brain drug delivery

The transport of drugs across the cell membrane using transport systems has been a great success in drug development. The BBB is a bottleneck in brain drug development and delivery as it excludes nearly all large-molecule neurotherapeutics and about 98% of all small molecule drugs [127]. In this context, more and more attention has been paid to manipulating transporters in the BBB to promote drug delivery into the brain [18,30,128]. SLCs recognize certain substrate structures, and most effective drugs for brain disorders possess N (amine)-containing groups, which suggest SLCs in the BBB may interact with N-containing groups [128]. Therefore, incorporating N-containing groups into known substrates of SLCs in the BBB will be beneficial for the development of drugs for central nervous system disorders.

Research targeting SLCs will help to promote the development of brain disorder drugs; screening candidate drugs for high affinity targeting of the BBB will be crucial for the development of effective treatment of brain disorders [129]. Indeed, many drugs that have affinity for receptors and

---

Fig. 2 – Examples of SLC mediated drug transport across the blood-brain barrier and in glioblastomas and neurons. Three strategies of SLC mediated drug transportation in the brain. 1. SLC7A5 mediated liposomal drug carrier system. (1) An L-DOPA functionalized amphiphile is loaded with STAT3 inhibitor WP1066, a drug for the treatment of glioblastoma, and is modified with DSPE-(PEG)27-NH2, a reagent to enhance the circulation stability of the liposomes; (2) SLC7A5 mediates the uptake of Amphi-DOPA into the BBB endothelial cells; (3) Released Amphi-DOPA is recognized by SLC7A5 localized to the membrane of glioblastoma cells and is taken up by tumor cells; (4) WP1066 is released from the Amphi-DOPA and induces tumor cell death by inhibiting the STAT3 pathway. 2. SLC22A5 mediates the nanoparticle drug carrier system. (1) L-carnitine-conjugated poly(lactic-co-glycolic acid) (PLGA, biodegradable synthetic polymer) nanoparticles (LC-PLGA NPs) are developed which are loaded with paclitaxel, an anti-glioma drug; (2) SLC22A5 mediates the uptake of LC-PLGA NPs into the BBB endothelial cells; (3) Released LC-PLGA NPs are recognized by SLC22A5 localized in the membrane of glioblastoma cells and are taken up by tumor cells; (4) paclitaxel is released from the LC-PLGA NPs, leading to inhibition of tumor cell proliferation and induction of apoptosis by the anti-microtubule effect. 3. SLC7A5 mediates prodrug carrier system. L-DOPA is a prodrug of the neurotransmitters dopamine. It is transported across the BBB and taken up by neurons via SLC7A5. L-DOPA is converted to dopamine for the treatment of Parkinson’s disease.
SLCs in the brain have been identified [130,131]. Gabapentin, a structural analog of GABA, increases expression of GABA_A receptors [132] and is used in the treatment of epilepsy [133]. Although it had been shown that Gabapentin has high permeability across the BBB, the mechanism of this action was not well demonstrated until Dickens et al. showed that SLC7A5 transports Gabapentin as a substrate [134]. Another SLC7A5 drug substrate is L-DOPA, which is the most effective drug available for the treatment of PD [135,136].

Glioblastomas are the most aggressive primary brain tumor in adults, with only 3–5% survivability beyond 5 years [137]. Few successes of systemic chemotherapy against glioblastoma have been reported, and this is partly due to the poor drug delivery into glioblastoma tissue and toxicity of drugs to brain cells [138]. SLC7A5 is expressed in both the BBB and glioblastoma and transports L-DOPA as a substrate, which has contributed to the construction of a SLC7A5 mediated liposomal drug carrier system that was prepared from an L-DOPA functionalized amphiphile [131]. This strategy provides the potential for systemic chemotherapy of glioblastoma. Nanoparticles conjugated to carrier transporter substrates represent another potential drug carrier system for the treatment of glioblastomas. SLC22A5 is expressed in both BBB and glioblastoma and transports L-carnitine. L-carnitine-conjugated nanoparticles were applied to target glioma cells for drug delivery via SLC22A5 (Fig. 2) [33].

3.3. SLC structure determination for drug design

Our understanding of the molecular assembly and transport mechanisms of SLCs was limited until a number of crystal structures of SLCs were solved [139]. X-ray crystallography, NMR spectroscopy and cryo-electron microscopy have helped to solve SLC structures despite difficulties, such as the poor stability of membrane proteins and purification and crystallization difficulties [139]. The revealed architectural features of SLCs provide unprecedented insights into their molecular mechanisms and provide templates for improving preclinical drugs. Drew et al. compared alternating-access mechanisms, including the rocker-switch model, the rocking-bundle model, and the elevator model, in relation to the crystal structures of several transporters that have been reported [13]. Bai et al. sorted the SLC structures into four groups with different protein folds, including the MFS (major facilitator superfamily) fold, the LeuT (leucine transporter) fold, other antiparallel folds and others [139]. SLC7A5, which is crucial for brain drug delivery, as discussed in other parts of this article, forms a disulfide-linked heterodimer with SLC3A2. This SLC7A5:SLC3A2 complex has been revealed by single-particle cryo-EM and explains the organization of the unique glycoprotein-solute carrier complex [140,141]. By comparative modeling, virtual screening, and experimental validation, four SLC7A5 ligands have been identified [142]. Computational modeling based on structural biology will accelerate the substrate prediction and drug screening of small molecule libraries for brain drug discovery [19,143].

4. Conclusions and future prospects

There are hundreds of SLCs in the brain that play important roles in the distribution of multiple substrates. The study of SLCs promotes the understanding of the substrates’ roles in brain, as well as the role of transporters in brain homeostasis. SLCs can serve as drug targets or facilitate drug delivery across the BBB and into brain cells. Despite the continuous efforts that have been made to demonstrate the transporting mechanisms, we are far from understanding the SLC transport system in the brain. The physiological function, regulation in disease, and drug deposition of most SLCs expressed in the brain remain to be studied. An understanding of SLCs in aspects of physiology and pharmacology will help to promote drug discovery. Pardridge (2015) introduced a high throughput screening of a small molecule neuropharmacological library for drugs interacting with SLCs expressed in the BBB [129], in which a mammalian host cell line overexpressing SLC transporters was used to screen small molecule libraries. Tashima reviewed transporter-conscious drug design to provide advantages in absorption, distribution, excretion, and toxicity of drugs, and especially emphasized the recognition of the N-containing group of substrates by the transporters [128]. Novel brain pharmaceutical agent discovery and delivery will be triggered based on the demonstration of transporting mechanisms, drug screening approaches, and transporter-conscious drug design to enhance the quality of life for patients suffering from brain disorders.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This work was supported by Nation Science and Technology Major Projects for Major New Drugs Innovation and Development (2018ZX0911003-004-002 to L.C.), Ministry of Science and Technology of China National Key R&D Programs (2018YFA0506903 to L.C.), and National Natural Science Foundation of China grants (91857108 to L.C.).

References

[1] Hediger MA, Clemenson B, Burford RE, Bruford EA. The ABCs of membrane transporters in brain and disease (SLC series): introduction. Mol Aspects Med 2013;34(2–3):95–107.
[2] Zhang Y, Zhang Y, Sun K, Meng Z, Chen L. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development. J Mol Cell Biol. 2019;11(1):1–13.
[3] Cesar-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, et al. A call for systematic research on solute carriers. Cell 2015;162(3):478–87.
[4] Song W, Luo Q, Zhang Y, Zhou L, Liu Y, Ma Z, et al. Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. PLoS Biol 2019;17(1):e2006571.
[5] Hall C, Wolfe H, Wells A, Chien HC, Colas C, Schlessinger A, et al. l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. Bioorg Med Chem Lett; 2019. doi:10.1016/j.bmcl.2019.06.033.
[6] Guan X, Luo L, Begum G, Kohanbash G, Song Q, Rao A, et al. Elevated na/h exchanger 1 (SLC9A1) emerges as a
marker for tumorigenesis and prognosis in gliomas. J Exp Clin Cancer Res 2018;37(1):255.

[7] Li Q, Zhou T, Wu F, Li N, Wang R, Zhao Q, et al. Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery. Drug Metab Rev 2018;50(4):430–47.

[8] LeVine MV, Cuenet MA, Khelashvili G, Weinstein H. Allosteric mechanisms of molecular machines at the membrane: transport by sodium-coupled symporters. Chem Rev 2016;116(11):6552–87.

[9] Coccu E, Kim JY, Bai Y, Fabia N. Role of passive diffusion, transporters, and membrane trafficking-mediated processes in cellular drug transport. Clin Pharmacol Ther 2017;101(1):121–9.

[10] Henderson PF. Membrane transport: energetics and overview. In: Roberts GCK, editor. Encyclopedia of biophysics. Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 1496–504.

[11] Locher KP. Mechanistic diversity in ATP-binding cassette (ABC) transporters. Nat Struct Mol Biol 2016;23(6):487–93.

[12] Hossain KR, Clarke RJ. General and specific interactions of the phospholipid bilayer with P-type ATPases. Biophys Rev 2019;11(3):353–64.

[13] Drew D, Bouldier O. Shared molecular mechanisms of membrane transporters. Annu Rev Biochem 2016;85:543–72.

[14] Takahashi K, Foster JB, Lin CL. Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. Cell Mol Life Sci 2015;72(18):3489–506.

[15] Perland E, Fredriksson R. Classification systems of secondary active transporters. Trends Pharmacol Sci 2017;38(3):305–15.

[16] Couillon L, Bouret Y, Marchiq I, Pouyssegur J. Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism. Biochim Biophys Acta 2016;1863(10):2465–80.

[17] Rask-Andersen M, Masuram S, Fredriksson R, Schioth HB. Solute carriers as drug targets: current use, clinical trials and prospective. Mol Aspects Med 2013;34(2–3):702–10.

[18] Brzica H, Abdullahi W, Ibbotson K, Ronaldson PT. Role of transporters in central nervous system drug delivery and blood-brain barrier protection: relevance to treatment of stroke. J Cent Nerv Syst Dis 2017;9:11797535177693820.

[19] Turkova A, Zdražil B. Current advances in studying clinically relevant solutes of the solute carrier family connecting computational modeling and data science. Comput Struct Biotechnol J 2019;17:390–405.

[20] Al-Abdulla R, Perez-Silva L, Abete I, Romero MR, Briz O, Marín JG. Unraveling 'the cancer genome atlas' information on the role of SLC transporters in anticancer drug uptake. Expert Rev Clin Pharmacol 2019;12(4):329–41.

[21] Liang Y, Li S, Chen L. The physiological role of drug transporters. Protein Cell 2015;6(5):334–50.

[22] Chen L, Chen XY, Huang X, Song BL, Wang Y, Wang Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci 2019;62(11):1420–58.

[23] Spencer JL, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 2018;89(1):42–52.

[24] Lee WLA, Michael-Titus AT, Shah DK. Hypoxic-isaemic encephalopathy and the blood-brain barrier in neonates. Dev Neurosci 2017;39(1–4):49–58.

[25] Wong KH, Riaz MK, Xie Y, Zhang X, Liu Q, Chen H, et al. Review of current strategies for delivering alzheimer’s disease drugs across the blood-brain barrier. Int J Mol Sci 2019;20(2):E381.
essential players in the somatosensory systems. Prog Neurobiol 2018;171:72–89.

[44] Aubrey KR. Presynaptic control of inhibitory neurotransmitter content in viat containing synaptic vesicles. Neurochem Int 2016;98:94–102.

[45] Boulland JL, Jenstad M, Boekel AJ, Wouterlood FG, Edwards RH, Storm-Mathisen J, et al. Vesicular glutamate and gaba transporters sort to distinct sets of vesicles in a population of presynaptic terminals. Cereb Cortex 2009;19(1):241–8.

[46] Zander JF, Munster-Wadowski A, Brunk I, Pahner I, Gomez-Lira G, Heinemann U, et al. Synaptic and vesicular coexistence of glutamate and gaba in selected excitatory and inhibitory synapses. J Neurosci 2010;30(22):7634–45.

[47] Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: gaba and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 2019;102(1):75–90.

[48] Tordj J, Totterdell S, Wojcik SM, Brose N, Elzalde N, Lasheras B, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007;25(1):281–90.

[49] Janickova H, Prado VF, Prado MAM, El Nestikawy S, Bernard V. Vesicular acetylcholine transporter (VACHT) over-expression induces major modifications of striatal cholinergic interneuron morphology and function. J Neurochem 2017;142(6):857–75.

[50] Padua-Reis M, Aquino NS, Oliveira VEM, Szawka RE, Prado MAM, Prado VF, et al. Reduced vesicular acetylcholine transporter favors antidepressant behaviors and modulates serotonin and dopamine in female mouse brain. Behav Brain Res 2017;330:127–32.

[51] Pramod AB, Foster J, Carvelli L, Henry LK. SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med 2013;34(2–3):197–219.

[52] Rudnick G, Kramr R, Blakely RD, Murphy DL, Verrey F. The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflugers Arch 2014;466(1):25–42.

[53] Salatino-Oliveira A, Rohde LA, Hutz MH. The dopamine transporter role in psychiatric phenotypes. Am J Med Genet B Neuropsychiatr Genet 2018;177(2):213–31.

[54] Efmanova E, Gainetdinov RR, Budynin EA, Sotnikova TD. Dopamine transporter mutant animals: a translational perspective. J Neurogenet 2016;30(1):5–15.

[55] Traiffort E, O’Regan S, Ruat M. The choline transporter-like family SLC44: properties and roles in human diseases. Mol Aspects Med 2015;34(2–3):646–54.

[56] Wang L, Pavlou S, Du X, Bhuckory M, Xu H, Chen M. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Mol Neurodegener 2019;14(1):2.

[57] Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011;14(6):724–31.

[58] Magistretti PJ, Allaman I. A cellular perspective on brain energy metabolism and functional imaging. Neuron. 2015;86(4):883–901.

[59] Szablevski L. Glucose transporters in brain: in health and in Alzheimer’s disease. J Alzheimers Dis 2017;55(4):1307–20.

[60] Castellotti B, Ragona F, Freni E, Solazzi R, Ciardullo S, Tricomi G, et al. Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes. J Neurol 2019;266(6):1439–48.

[61] Espinoza-Rojo M, Iturralde-Rodriguez KL, Chanez-Cardenas ME, Ruiz-Tachiquin ME, Aguilera P. Glucose transporters regulation on ischemic brain: possible role as therapeutic target. Cent Nerv Syst Agents Med Chem 2010;10(4):317–25.

[62] Koch H, Weber YG. The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav 2019;91:90–3.

[63] Hja MK, Morrison BM. Glia-neuron energy metabolism in health and diseases: new insights into the role of nervous system metabolic transporters. Exp Neurol 2018;309:23–31.

[64] Sonnay S, Poiriot J, Just N, Clerc AC, Gruetter R, Rainer G, et al. Astrocytic and neuronal oxidative metabolism are coupled to the rate of glutamate-glutamine cycle in the tree shrew visual cortex. Glia 2018;66(3):477–91.

[65] Suzuki A, Stern SA, Bozdogi O, Huntley GW, Walker RH, Magistretti PJ, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011;144(5):810–23.

[66] Diel CA. Does shuffling of glycogen-derived lactate from astrocytes to neurons take place during neurotransmission and memory consolidation? J Neurosci Res 2019;97(8):863–82.

[67] Sibson NR, Dhanakhar A, Mason GF, Rothman DL, Behar KI, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 1998;95(15):316–21.

[68] Broer S, Brookes N. Transfer of glutamine between astrocytes and neurons. J Neurochem 2001;77(3):705–19.

[69] Leke R, Schousboe A. The glutamine transporters and their role in the glutamate/GABA-glutamine cycle. Adv Neurobiol 2016;13:223–57.

[70] Jenstad M, Chaudhry FA. The amino acid transporters of the glutamate/GABA-glutamine cycle and their impact on insulin and glucagon secretion. Front Endocrinol (Lausanne) 2013;4:199.

[71] Gilddon CM, Shao Z, LeMaitre JL, Anderson CM. Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain. J Neurochem 2009;108(2):372–83.

[72] Omote H, Miyagi T, Hiasa M, Juge N, Moriyama Y. Structure, function, and drug interactions of neurotransmitter transporters in the postgenomic era. Annu Rev Pharmacol Toxicol 2016;56:385–402.

[73] Gasnier B. The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids. Pflugers Arch 2004;447(5):756–58.

[74] Lawal HO, Krantz DE. SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med 2013;34(2–3):360–72.

[75] Eiden LE, Schafer MK, Weihe E, Schutz B. The vesicular amine transporter family (SLC18): amine/proton antipoters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 2004;447(5):636–40.

[76] Morris ME, Rodriguez-Cruz V, Felmlee MA. SLC and abc transporters: expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers. AAPS J 2017;19(5):1317–31.

[77] Cardville WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32(11):1959–72.

[78] Abdullaah W, Davis TP, Ronaldson PT. Functional expression of P-glycoprotein and organic anion transporting polypeptides at the blood-brain barrier: understanding transport mechanisms for improved CNS drug delivery? AAPS J 2017;19(4):931–9.

[79] Billington S, Salphati L, Hop C, Chu X, Evers R, Burdette D, et al. Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics. Clin Pharmacol Ther 2019;106(1):228–37.

[80] Meszaros M, Porkolab G, Kiss L, Pilbat AM, Kota Z, Kuphar Z, et al. Niosomes decorated with dual ligands targeting brain
endothelial transporters increase cargo penetration across the blood-brain barrier. Eur J Pharm Sci 2018;123:228–40.

[81] Nigam SK. What do drug transporters really do? Nat Rev Drug Discov 2015;14(1):29–44.

[82] Lei HT, Ma J, Sanchez Martinez S, Gonen T. Crystal structure of arginine-bound lysosomal transporter SLC38A9 in the cytosol-open state. Nat Struct Mol Biol 2018;25(6):522–7.

[83] Patching SG. Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol 2017;54(2):1046–77.

[84] Spicarić MC, von Gaudecker JR, Jurasek L, Clarke DF, Burneo J, Viduareje J. Global health and epilepsy: update and future directions. Curr Neurol Neurosci Rep 2019;19(6):30.

[85] Loscher W, Puskarjov M, Kaila K. Cation–chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropsychopharmacology 2013;38:62–74.

[86] Moore YE, Kelley MR, Brandon NJ, Deeb TZ, Moss SJ. Seizure control of KCC2: a new therapeutic target for epilepsy. Trends Neurosci 2017;40(9):555–71.

[87] Lykke K, Tøllner K, Feit PW, Erker T, Macaulay N, Loscher W. The search for NKCC1-selective drugs for the treatment of epilepsy: structure–function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation–chloride cotransporter NKCC1A. Epilepsy Behav. 2016;59:42–9.

[88] Gharaee-Khani A, Tafakkori A, Agah E, Aghamollaii V, Kebrarzadeh A, Hadjighasem M. A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy. CNS Drugs 2019;33(3):283–91.

[89] Eid T, Gruenbaum SE, Dhaer R, Lee TW, Zhou Y, Danbolt NC. The glutamate-glutamine cycle in epilepsy. Adv Neurobiol 2016;13:351–400.

[90] Stergachis AB, Fuji-Go-Migone J, Gyimesi G, Fuster D, Albano G, Troxler M, et al. Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism. Ann Neurol 2019;85(6):921–6.

[91] Zhang Y, Dong H, Duan L, Yuan G, Liang W, Li Q, et al. SLC1A2 mediates refractory temporal lobe epilepsy with an initial precipitating injury by targeting the glutamatergic synapse pathway. iJUBMB Life 2019;7(2):213–22.

[92] Mattison KA, Butler KM, Inglis DA, Dayan O, Boussidan H, Bhambani V, et al. SLC6A1 variants identified in epilepsy patients reduce gamma-aminobutyric acid transport. Epilepsia 2018;59(9):e135–e441.

[93] Dikow N, Maas B, Karch S, Granzow M, Janssen JW, Jauch A, et al. 3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior. Am J Med Genet A 2014;164A(12):3061–8.

[94] Hardies K, de Kovel CG, Weckhuysen S, Asselbergh B, Geuens T, Deconinck T, et al. Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia. Brain 2015;138(Pt 11):3238–50.

[95] Thevenon J, Milh M, Feillet F, St-Onge J, Duffour Y, Juge C, et al. Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life. Am J Hum Genet 2014;95(1):113–20.

[96] Weeke LC, Brilstra E, Braun KP, Zonneveld-Huijssen E, Salomons GS, Koelman BP, et al. Punctate white matter lesions in full-term infants with neonatal seizures associated with SLC13A5 mutations. Eur J Paediatr Neurol. 2017;21(2):396–403.

[97] Bhutia YD, Kopel JJ, Lawrence J, Neugebauer V, Ganapathy V. Plasma membrane Na(+)-coupled citrate transporter (SLC13A5) and neonatal epileptic encephalopathy. Molecules 2017;22(9):378.

[98] Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O‘Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 2014;34(26):11929–47.

[99] Pajor AM. Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family. Pfugers Arch 2014;466(1):119–30.

[100] Bainbridge MN, Cooney E, Miller M, Kennedy AD, Wulff JE, Dounti T, et al. Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle. Mol Genet Metab. 2017;121(4):314–19.

[101] Liang D, Lu H. Salivary biological markers for Alzheimer’s disease. Arch Oral Biol 2019;105:5–12.

[102] Liu Y, Liu F, Iqbal K, Grunke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 2008;582(2):359–64.

[103] Piert M, Koepe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer’s disease determined by dynamic FDG-PET. J Nucl Med 1996;37(2):201–8.

[104] Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer’s disease. Int J Mol Sci 2012;13(10):42629–55.

[105] Hoornmans CR, Graven C, Dederen PJ, Tanha H, van Groen T, Kiliaan AJ. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice. Brain Res 2007;1181:93–103.

[106] Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, et al. Peripheral brain-derived neurotrophic factor levels in Alzheimer’s disease and mild cognitive impairment: a comprehensive systematic review and meta-analysis. Mol Neurobiol 2017;54(9):7297–311.

[107] Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs 2003;17(9):641–52.

[108] Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 1996;40(5):759–66.

[109] Wolters LR, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 2010;69(7):667–76.

[110] Jacob CP, Koutsilierei E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimers Dis 2007;11(1):97–116.

[111] Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, et al. Cognitive decline in Alzheimer’s disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 2009;29(41):12957–69.

[112] Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015;386(9996):896–912.

[113] Stoessl AJ. Neuroimaging in Parkinson’s disease: from pathology to diagnosis. Parkinsonism Relat Disord 2012;18(Suppl 1):S55–9.

[114] Fu JF, Klyuzhin I, McKenzie J, Neilson N, Shahinfard E, Dinelle K, et al. Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson’s disease induced presynaptic alterations. Neuroimage Clin 2019;23:101856.

[115] McHugh PC, Buckley DA. The structure and function of the dopamine transporter and its role in CNS diseases. Vitam Horm 2015;98:339–69.

[116] Ikeda K, Ebina J, Kawabe K, Iwasaki Y. Dopamine
